Gilead Sciences, Inc. (GILD) stock
GILDNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Oct 30, 2026Score 11/30104% above fair value
$168.08+0.13 (+0.08%)
Close on Nov 13, 2026Market cap $208.48BP/E –Yield 1.88%
Gilead Sciences gross margin
Gross margin is gross profit as a percentage of revenue.
Gilead Sciences's gross margin for the twelve months ending Sep 30, 2026 was 79.9%. For fiscal 2025 it was 78.8%, against 78.3% the year before. The highest annual figure on record is 87.7% in fiscal 2015.
Annual gross margin
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 78.8% | +0.6 |
| FY2024 | Dec 31, 2024 | 78.3% | +2.2 |
| FY2023 | Dec 31, 2023 | 76.0% | −3.2 |
| FY2022 | Dec 31, 2022 | 79.3% | +3.4 |
| FY2021 | Dec 31, 2021 | 75.8% | −5.7 |
| FY2020 | Dec 31, 2020 | 81.5% | +2.3 |
| FY2019 | Dec 31, 2019 | 79.2% | +1.1 |
| FY2018 | Dec 31, 2018 | 78.1% | −5.2 |
| FY2017 | Dec 31, 2017 | 83.3% | −2.7 |
| FY2016 | Dec 31, 2016 | 86.0% | −1.7 |
| FY2015 | Dec 31, 2015 | 87.7% | +2.9 |
| FY2014 | Dec 31, 2014 | 84.8% | +10.3 |
| FY2013 | Dec 31, 2013 | 74.5% | −0.1 |
| FY2012 | Dec 31, 2012 | 74.5% | −0.1 |
| FY2011 | Dec 31, 2011 | 74.7% | −1.8 |
| FY2010 | Dec 31, 2010 | 76.5% | −0.8 |
| FY2009 | Dec 31, 2009 | 77.2% | −1.6 |
| FY2008 | Dec 31, 2008 | 78.9% | −3.0 |
| FY2007 | Dec 31, 2007 | 81.8% | – |
Quarterly gross margin
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | 81.1% | +1.3 |
| Q2 FY2026 | Jun 30, 2026 | 79.8% | +1.0 |
| Q1 FY2026 | Mar 31, 2026 | 79.2% | +2.3 |
| Q4 FY2025 | Dec 31, 2025 | 79.5% | +0.4 |
| Q3 FY2025 | Sep 30, 2025 | 79.8% | +0.7 |
| Q2 FY2025 | Jun 30, 2025 | 78.8% | +1.0 |
| Q1 FY2025 | Mar 31, 2025 | 76.9% | +0.1 |
| Q4 FY2024 | Dec 31, 2024 | 79.1% | +8.5 |
| Q3 FY2024 | Sep 30, 2024 | 79.1% | +1.3 |
| Q2 FY2024 | Jun 30, 2024 | 77.8% | −0.4 |
| Q1 FY2024 | Mar 31, 2024 | 76.8% | −1.2 |
| Q4 FY2023 | Dec 31, 2023 | 70.6% | −10.5 |
| Q3 FY2023 | Sep 30, 2023 | 77.8% | −2.4 |
| Q2 FY2023 | Jun 30, 2023 | 78.1% | +1.2 |
| Q1 FY2023 | Mar 31, 2023 | 77.9% | −0.4 |
| Q4 FY2022 | Dec 31, 2022 | 81.1% | +17.4 |
| Q3 FY2022 | Sep 30, 2022 | 80.2% | −3.3 |
| Q2 FY2022 | Jun 30, 2022 | 77.0% | −0.7 |
| Q1 FY2022 | Mar 31, 2022 | 78.4% | −0.4 |
| Q4 FY2021 | Dec 31, 2021 | 63.7% | −16.2 |
| Q3 FY2021 | Sep 30, 2021 | 83.5% | +2.1 |
| Q2 FY2021 | Jun 30, 2021 | 77.6% | −0.2 |
| Q1 FY2021 | Mar 31, 2021 | 78.8% | −2.3 |
| Q4 FY2020 | Dec 31, 2020 | 79.9% | +9.9 |
| Q3 FY2020 | Sep 30, 2020 | 81.4% | +1.4 |
| Q2 FY2020 | Jun 30, 2020 | 77.8% | −3.2 |
| Q1 FY2020 | Mar 31, 2020 | 81.1% | +0.7 |
| Q4 FY2019 | Dec 31, 2019 | 70.0% | −1.0 |
| Q3 FY2019 | Sep 30, 2019 | 80.0% | +1.9 |
| Q2 FY2019 | Jun 30, 2019 | 81.0% | +4.1 |
| Q1 FY2019 | Mar 31, 2019 | 80.3% | +1.7 |
| Q4 FY2018 | Dec 31, 2018 | 70.9% | −6.1 |
| Q3 FY2018 | Sep 30, 2018 | 78.1% | −4.4 |
| Q2 FY2018 | Jun 30, 2018 | 76.9% | −6.0 |
| Q1 FY2018 | Mar 31, 2018 | 78.6% | −4.7 |
| Q4 FY2017 | Dec 31, 2017 | 77.0% | −6.9 |
| Q3 FY2017 | Sep 30, 2017 | 82.5% | – |
| Q2 FY2017 | Jun 30, 2017 | 82.9% | – |
| Q1 FY2017 | Mar 31, 2017 | 83.3% | – |
| Q4 FY2016 | Dec 31, 2016 | 83.9% | – |
See a number that looks wrong?